Micro- and Nanofluidic Technology Innovations for Infectious Disease Control and Management

Micro- and Nanofluidic Technology Innovations for Infectious Disease Control and Management

Advanced microfluidics-based nucleic acid testing and immunoassay platforms are enabling multiplexed detection with rapid turnaround

RELEASE DATE
23-Jun-2022
REGION
Global
Research Code: DA5A-01-00-00-00
SKU: HC03554-GL-TR_26656
$4,950.00
In stock
SKU
HC03554-GL-TR_26656
$4,950.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

The rise in both global population and travel is contributing to the increase in spread of infectious diseases. Rapid and accurate identification of the infectious pathogens are imperative for timely intervention, better patient outcomes, and control and management of the spread of the infection. Conventional infectious disease diagnoses are performed in centralized labs; they have a long turnaround time and require expertise. Microfluidics-based infectious disease diagnostics, on the other hand, can enable multiplexed pathogen detection, rapid turnaround, and results at the point of care; they help healthcare providers take quick clinical decisions on treatment or isolation, and enable a lower rate of incidence.
In this report, the microfluidics-based infectious disease diagnostic innovations have been segmented by the property/phenomenon exploited for the isolation or identification. This Frost & Sullivan research service analyzes the drawbacks of conventional infectious disease diagnosis and the benefits of employing microfluidics in infectious disease diagnostics. It also covers growth drivers and the restraints in the micro-/nanofluidic infectious disease diagnostics industry, emerging microfluidic technologies, and companies to action. Technology adoption trends, innovation indicators, and the commercialization voids in the micro-/nanofluidic infectious disease diagnostics are also analyzed. Growth opportunities offered by advanced loop-mediated isothermal amplification platforms, rapid antimicrobial resistance detection platforms, and advanced infectious pathogen biosensors are also discussed. The study also includes an IP landscape analysis of the patents filed over the last 6 years, critical success factors and strategic recommendations.

The rise in both global population and travel is contributing to the increase in spread of infectious diseases. Rapid and accurate identification of the infectious pathogens are imperative for timely intervention, better patient outcomes, and control and management of the spread of the infection. Conventional infectious disease diagnoses are performed in centralized labs; they have a long turnaround time and require expertise. Microfluidics-based infectious disease diagnostics, on the other hand, can enable multiplexed pathogen detection, rapid turnaround, and results at the point of care; they help healthcare providers take quick clinical decisions on treatment or isolation, and enable a lower rate of incidence. In this report, the microfluidics-based infectious disease diagnostic innovations have been segmented by the property/phenomenon exploited for the isolation or identification. This Frost & Sullivan research service analyzes the drawbacks of conventional infectious disease diagnosis and the benefits of employing microfluidics in infectious disease diagnostics. It also covers growth drivers and the restraints in the micro-/nanofluidic infectious disease diagnostics industry, emerging microfluidic technologies, and companies to action. Technology adoption trends, innovation indicators, and the commercialization voids in the micro-/nanofluidic infectious disease diagnostics are also analyzed. Growth opportunities offered by advanced loop-mediated isothermal amplification platforms, rapid antimicrobial resistance detection platforms, and advanced infectious pathogen biosensors are also discussed. The study also includes an IP landscape analysis of the patents filed over the last 6 years, critical success factors and strategic recommendations.--BEGIN PROMO--

The spread of infectious diseases is increasing with the rise in global population and global travel. Rapid and accurate identification of the infectious pathogens are imperative for timely interventions enabling better patient outcomes and efficient control and management of the spread of the infection. Conventional infectious disease diagnosis are performed in centralized labs. They have a long turnaround time and requires expertise. Microfluidics-based infectious disease diagnostics can enable multiplexed pathogen detection, rapid turnaround and results at the point of care. It allows healthcare providers to take quick clinical decisions on treatment or isolation, and prevent endemic or epidemic or pandemic. In this report, the microfluidic-based infectious disease diagnostic innovations have been segmented based on the property/phenomena exploited for the isolation or identification. This Frost & Sullivan research service analyzes the drawbacks of conventional infectious disease diagnosis and the benefits of employing microfluidics in infectious disease diagnostics. The growth drivers and the restraints in the micro/nanofluidic infectious disease diagnostics industry are detailed. The emerging microfluidic technologies enabling infectious disease diagnosis and the companies to action are explored. The technology adoption trends, innovation indicators and the commercialization voids in the micro/nanofluidic infectious disease diagnostics are put forth. Growth opportunities offered by advanced loop-mediated isothermal amplification platforms, rapid antimicrobial resistance detection platforms and advanced infectious pathogen biosensors are discussed. The study also includes an IP landscape analysis of the patents filed over the past 6 years. Critical success factors and strategic recommendations are also discussed.

More Information
Author Sneha Maria Mariawilliam
Industries Healthcare
No Index No
Is Prebook No
Podcast No
WIP Number DA5A-01-00-00-00